Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
    Primary Cutaneous Melanoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    Patients must have a stage II primary invasive cutaneous melanoma with Breslow thickness >2mm without ulceration), or >1mm (with ulceration only) and subsequent histopathological analysis as determined by diagnostic biopsy. Must have a primary melanoma that is cutaneous. An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma. Surgery (which refers to the staging sentinel node biopsy and wide local excision as these are both to be done on the same day) must be completed within 120 days of the original diagnosis.

You may not be eligible for this study if the following are true:

  • Uncertain diagnosis of melanoma i.e. so-called ‘melanocytic lesion of unknown malignant potential’. Patient has already undergone wide local excision at the site of the primary index lesion. Patient unable or ineligible to undergo staging sentinel lymph node biopsy of the primary index lesion. History of previous or concurrent (i.e., second primary) invasive melanoma.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.